Harmony Biosciences Holdings Inc (OQ:HRMY)

Sector:  Healthcare Industry:  Pharmaceuticals
See Regulatory Filings on SEC
Company Contact
Address: 630 W Germantown Pike, Suite 215
Tel: N/A
Website: https://www.harmonybiosciences.com
IR: See website
Key People
Jeffrey M. Dayno
President, Chief Executive Officer, Director
Sandip S. Kapadia
Chief Financial Officer, Chief Administrative Officer
Kumar Budur
Chief Scientific Officer
Jeffrey Dierks
Chief Commercial Officer
Andrew Serafin
Chief Strategy Officer
Business Overview
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company. It is focused on developing and commercializing therapies for patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action designed to enhance histamine signaling in the brain by binding to H3 receptors. Its WAKIX is developed for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy and treatment of cataplexy in adult patients with narcolepsy. It also provides HBS-102, an investigational compound, which is a melanin-concentrating hormone receptor 1 (MCHR1) antagonist that targets MCH neurons in the brain. It also develops ZYN002, a pharmaceutically manufactured synthetic cannabidiol. It is also focused on the rare epilepsy franchise in its expanding late-stage pipeline of CNS assets: EPX-100 and EPX-200.
Financial Overview
For the three months ended 31 March 2024, Harmony Biosciences Holdings Inc revenues increased 30% to $154.6M. Net income increased 30% to $38.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Basic Earnings per Share excluding Extraordinary Items increased from $0.49 to $0.68.
Employees: 246 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $1,467M as of Mar 31, 2024
Annual revenue (TTM): $617.51M as of Mar 31, 2024
EBITDA (TTM): $228.06M as of Mar 31, 2024
Net annual income (TTM): $137.70M as of Mar 31, 2024
Free cash flow (TTM): $207.65M as of Mar 31, 2024
Net Debt Last Fiscal Year: N/A
Shares outstanding: 56,791,861 as of Apr 26, 2024
Index Membership: S&P 600 Small Cap
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.